Bristol-Myers Squibb

Bristol-Myers SquibbBristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

www.bms.com.

Bristol-Myers Squibb RSS Channel

Display # 
Title Published Date
Bristol-Myers Squibb reports second quarter financial results 29 July 2016
Bristol-Myers Squibb acquires Cormorant Pharmaceuticals 05 July 2016
Bristol-Myers Squibb and PsiOxus Therapeutics announce immuno-oncology clinical collaboration 30 June 2016
Ready. Raise. Rise. Campaign 06 May 2016
Bristol-Myers Squibb reports first quarter financial results 28 April 2016
Bristol-Myers Squibb to acquire Padlock Therapeutics, Inc. 23 March 2016
Bristol-Myers Squibb and LabCentral team up in Cambridge, Massachusetts to support promising biotech startup companies 07 March 2016
Bristol-Myers Squibb completes previously announced sale of its HIV R&D portfolio to ViiV Healthcare 22 February 2016
Bristol-Myers Squibb and Dana-Farber Cancer Institute enter into a collaboration agreement 16 February 2016
Bristol-Myers Squibb Foundation awards eight grants totaling nearly $11.5M to make lung and skin cancer screening 01 February 2016
Bristol-Myers Squibb to sell its HIV R&D portfolio to ViiV Healthcare 18 December 2015
Bristol-Myers Squibb and UCLA enter into a collaboration agreement 14 December 2015
Bristol-Myers Squibb Foundation marks World AIDS Day with grants totaling more than $3.5M 01 December 2015
Bristol-Myers Squibb to acquire Cardioxyl Pharmaceuticals, Inc. 02 November 2015
Bristol-Myers Squibb reports third quarter financial results 27 October 2015
Bristol-Myers Squibb's Opdivo (nivolumab) receives expanded FDA approval in previously-treated metastatic non-small cell lung cancer (NSCLC) 12 October 2015
Bristol-Myers Squibb and Moffitt Cancer Center enter into a collaboration agreement 25 September 2015
Bristol-Myers Squibb Employees cycle nearly 2,900 miles to raise money for cancer research 10 September 2015
Bristol-Myers Squibb establishes collaborative Immuno-Oncology Rare Population Malignancy (I-O RPM) program in the U.S. 04 August 2015
Lilly, Bristol-Myers Squibb Restructure Erbitux® (cetuximab) Collaboration in North America 16 April 2015

Most Popular Now

Novo Nordisk and Aarhus University …

Novo Nordisk and Aarhus University's Science and Technology faculty today signed a collaboration agreement to strengthen protein technology research and development. Unde...

Read more

AstraZeneca enters licensing agreem…

AstraZeneca today announced that it has entered into agreements that support its strategic focus on three main therapy areas; Respiratory, Inflammation and Autoimmunity, ...

Read more

Bristol-Myers Squibb acquires Cormo…

Bristol-Myers Squibb Company (NYSE:BMY) and Cormorant Pharmaceuticals announced today that Bristol-Myers Squibb has acquired all of the outstanding capital stock of Cormo...

Read more

Sanofi Pasteur signs research agree…

Sanofi and its vaccines global business unit Sanofi Pasteur announced today a Cooperative Research and Development Agreement with the Walter Reed Army Institute of Resear...

Read more

Merck and Pfizer initiate Phase III…

Merck KGaA, Darmstadt, Germany, and Pfizer (NYSE: PFE) have announced the initiation of a Phase III study, JAVELIN Ovarian 100, to evaluate the efficacy and safety of ave...

Read more

FDA advances Precision Medicine Ini…

In support of the President’s Precision Medicine Initiative, the U.S. Food and Drug Administration has issued two draft guidances that, when finalized, will provide a fle...

Read more

FDA approves first and only single …

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the Repatha® (evolocumab) PushtronexTM system (on-body infusor with pref...

Read more

Amgen and Daiichi Sankyo announce a…

Amgen (NASDAQ:AMGN) and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo; TSE 4568) today announced the execution of an exclusive agreement to commercialize nin...

Read more

Boehringer Ingelheim and Lilly anno…

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced a new collaboration on a Phase 1b study that will evaluate the safety and tolerability of BI 83...

Read more

Twisting and turning to target anti…

Researchers are getting closer to understanding how some natural antibiotics work so they can develop drugs that mimic them. A recent review commissioned by the British g...

Read more

Merck commits €1.5 million to the G…

Merck, a leading science and technology company, today announced it would continue to support the advancement of medical science in the field of fertility through the Gra...

Read more

Losing weight lowered levels of pro…

Overweight or obese women who lost weight through diet or a combination of diet and exercise also significantly lowered levels of proteins in the blood that help certain ...

Read more

Digest World Pharma Newsletter

Subscribe to our weekly Digest World Pharma Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]

© World Pharma News 2006 - 2016